As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. For the first time ever, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery.

This November, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug discovery across inflammatory, cardiovascular and metabolic indications and beyond.

Bringing together technical experts from Eli Lilly, AstraZenenca, Roche, ThirtyFiveBio, OMass Therapeutics and more, this Meeting aims to unlock previously undruggable targets, reveal the significance of genetic variants of GPCRs, showcase ground-breaking drug discovery tools and streamline the translation of small molecules and biologics into clinically successful therapies.

Join 70+ Senior Scientists, Heads and Directors of Drug Discovery, Biology, Chemistry and Pharmacology for 3 days of technical and data driven case studies and discussions, enabling you and your team to accelerate novel GPCR-targeted drug discovery.